سعر بريتوبرازان 20 مجم 14 قرص 2025

Vonoprazan 20 mg film-coated tablets (potassium-competitive acid blocker), box of 14 tablets, by Elixir Pharma, Egypt.

• Healing of all grades of erosive esophagitis and relief of associated heartburnPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Maintenance of healed erosive esophagitis and relief of associated heartburnPopulation: AdultsDailyMed (U.S. National Library of Medicine)
• Relief of heartburn associated with non-erosive gastroesophageal reflux diseasePopulation: AdultsDailyMed (U.S. National Library of Medicine)

• Serious adverse reactions described include acute tubulointerstitial nephritis, C. difficile-associated diarrhea, bone fracture, severe cutaneous reactions, vitamin B12 deficiency, hypomagnesemia and fundic gland polyps; gastritis among the most common in erosive esophagitis healing.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity to vonoprazan or any component (including anaphylactic shock).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Coadministration with rilpivirine-containing products.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Symptomatic response does not exclude gastric malignancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute tubulointerstitial nephritis; Clostridioides difficile-associated diarrhea; bone fracture with long-term use; severe cutaneous adverse reactions.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Rilpivirine-containing productsContraindicated combination (reduced rilpivirine exposure).DailyMed (U.S. National Library of Medicine)

• No adequate and well-controlled studies in pregnant women; available pharmacovigilance data are insufficient to evaluate drug-associated risk; a pregnancy exposure registry exists.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Vonoprazan is present in human milk at less than 0.03% of the maternal dose; no data on effects on the breastfed child or milk production.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Vonoprazan: Potassium-competitive acid blocker: inhibits the parietal-cell H+,K+-ATPase in a potassium-competitive manner, suppressing basal and stimulated acid secretion; does not require activation by acid (US label).